The uniqueness of Ophtha lies in its non-invasiveness, affordability, high content of information, five stage disease severity classification based on ETDRS grading & pathological feature segmentation techniques.Ophtha AES web application software allows uploading the fundus images (two images per eye) for the public directly and obtaining a system generated report on the analysis.
Tell us what do you know about Automatic Eye Screening technology for Diabetic Retinopathy.
AI Eye Screening System
As your Eyes be the windows to the world, AI based solutions are being designed, developed and trained to diagnose retinal associated diseases and disorders to treat populace for an affordable cost yet with accurate results. Thus, OPHTHA AES is capable of detecting conditions (automatically segmenting of pathological features) related to DR and detecting the existence of DR and pathological features (exudates, hemorrhages, microaneurysms, neovascularization) based on which the classification is done.
From retinal image screening to grading for DR standards to reporting and flagging, our system operates as a fully autonomous solution.
Our solution offers you with results of high performance figures including 87.7% validation accuracy and 81.1% test accuracy.
Your data is secured and confidential with us as Ophtha AES uses novel and effective encryption and decryption technologies end-to-end, with highest level of compliance.
According to WHO, Diabetic Retinopathy (DR) is the major cause of blindness among adult populations in the world which occurs as a complication of Diabetics. To overcome this global problem we have introduced an automatic DR screening application as a cost effective and high accuracy solution.
Vision makes an important contribution to the 2030 Agenda for Sustainable Development and cuts across many of the Sustainable Development Goals; from poverty reduction to economic growth and employment to education, gender and reducing inequalities.
Mobirise web page software - More info